MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury

Research output: Contribution to journalArticle

Standard

MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury. / Di Pietro, Valentina; Ragusa, Marco; Davies, David; Su, Zhangjie; Hazeldine, Jon; Lazzarino, Giacomo; Hill, Lisa J; Crombie, Nicholas; Foster, Mark; Purrello, Michele; Logan, Ann; Belli, Antonio.

In: Journal of Neurotrauma, Vol. 34, No. 11, 01.06.2017, p. 1948-1956.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Di Pietro, Valentina ; Ragusa, Marco ; Davies, David ; Su, Zhangjie ; Hazeldine, Jon ; Lazzarino, Giacomo ; Hill, Lisa J ; Crombie, Nicholas ; Foster, Mark ; Purrello, Michele ; Logan, Ann ; Belli, Antonio. / MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury. In: Journal of Neurotrauma. 2017 ; Vol. 34, No. 11. pp. 1948-1956.

Bibtex

@article{9ec9e4898c3e49c981d7fd38e0b4152d,
title = "MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury",
abstract = "Traumatic brain injury (TBI) is the leading cause of death and disability in people younger than 45 in Western countries. Despite many studies, no reliable biomarkers have been found to assess TBI severity and predict recovery. MicroRNA (miRNA) profiling has become widely used to identify biomarkers and therapeutic targets. Through use of the TaqMan Array Human MicroRNA A+B Cards, the expression of 754 miRNAs was analyzed in serum of five mild TBI (mTBI) patients with extra-cranial injury (EC), five severe TBI (sTBI) patients with EC, and five healthy volunteers (HV) at 1 day and 15 days post-injury. The aim was to find candidate biomarkers able to discriminate between mTBI and sTBI. Following this, it was possible to select 10 miRNAs for further study in an enlarged validation cohort of 120 patients by using single TaqMan assays at the following time-points: T0-1 h, T4-12 h, T48-72 h, and 15 days from the injury. Analysis revealed two miRNAs (miR-425-5p and miR-502) that were significantly downregulated (p < 0.05) in mTBI at early time-points and are ideal candidates for diagnosis of mTBI, and two miRNAs (miR-21 and miR-335) that were significantly upregulated (p < 0.01) and are valid biomarkers for the diagnosis of sTBI. In addition, miR-425-5p was a strong predictor of 6-month outcome at T0-1 h and T4-12 h, while miR-21 was predictive of the outcome at T4-12 h. The panel of selected miRNAs shows promise as biomarkers to discriminate mTBI from sTBI. In addition, the selected miRNAs represent new potential therapeutic targets.",
author = "{Di Pietro}, Valentina and Marco Ragusa and David Davies and Zhangjie Su and Jon Hazeldine and Giacomo Lazzarino and Hill, {Lisa J} and Nicholas Crombie and Mark Foster and Michele Purrello and Ann Logan and Antonio Belli",
year = "2017",
month = "6",
day = "1",
doi = "10.1089/neu.2016.4857",
language = "English",
volume = "34",
pages = "1948--1956",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert",
number = "11",

}

RIS

TY - JOUR

T1 - MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury

AU - Di Pietro, Valentina

AU - Ragusa, Marco

AU - Davies, David

AU - Su, Zhangjie

AU - Hazeldine, Jon

AU - Lazzarino, Giacomo

AU - Hill, Lisa J

AU - Crombie, Nicholas

AU - Foster, Mark

AU - Purrello, Michele

AU - Logan, Ann

AU - Belli, Antonio

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Traumatic brain injury (TBI) is the leading cause of death and disability in people younger than 45 in Western countries. Despite many studies, no reliable biomarkers have been found to assess TBI severity and predict recovery. MicroRNA (miRNA) profiling has become widely used to identify biomarkers and therapeutic targets. Through use of the TaqMan Array Human MicroRNA A+B Cards, the expression of 754 miRNAs was analyzed in serum of five mild TBI (mTBI) patients with extra-cranial injury (EC), five severe TBI (sTBI) patients with EC, and five healthy volunteers (HV) at 1 day and 15 days post-injury. The aim was to find candidate biomarkers able to discriminate between mTBI and sTBI. Following this, it was possible to select 10 miRNAs for further study in an enlarged validation cohort of 120 patients by using single TaqMan assays at the following time-points: T0-1 h, T4-12 h, T48-72 h, and 15 days from the injury. Analysis revealed two miRNAs (miR-425-5p and miR-502) that were significantly downregulated (p < 0.05) in mTBI at early time-points and are ideal candidates for diagnosis of mTBI, and two miRNAs (miR-21 and miR-335) that were significantly upregulated (p < 0.01) and are valid biomarkers for the diagnosis of sTBI. In addition, miR-425-5p was a strong predictor of 6-month outcome at T0-1 h and T4-12 h, while miR-21 was predictive of the outcome at T4-12 h. The panel of selected miRNAs shows promise as biomarkers to discriminate mTBI from sTBI. In addition, the selected miRNAs represent new potential therapeutic targets.

AB - Traumatic brain injury (TBI) is the leading cause of death and disability in people younger than 45 in Western countries. Despite many studies, no reliable biomarkers have been found to assess TBI severity and predict recovery. MicroRNA (miRNA) profiling has become widely used to identify biomarkers and therapeutic targets. Through use of the TaqMan Array Human MicroRNA A+B Cards, the expression of 754 miRNAs was analyzed in serum of five mild TBI (mTBI) patients with extra-cranial injury (EC), five severe TBI (sTBI) patients with EC, and five healthy volunteers (HV) at 1 day and 15 days post-injury. The aim was to find candidate biomarkers able to discriminate between mTBI and sTBI. Following this, it was possible to select 10 miRNAs for further study in an enlarged validation cohort of 120 patients by using single TaqMan assays at the following time-points: T0-1 h, T4-12 h, T48-72 h, and 15 days from the injury. Analysis revealed two miRNAs (miR-425-5p and miR-502) that were significantly downregulated (p < 0.05) in mTBI at early time-points and are ideal candidates for diagnosis of mTBI, and two miRNAs (miR-21 and miR-335) that were significantly upregulated (p < 0.01) and are valid biomarkers for the diagnosis of sTBI. In addition, miR-425-5p was a strong predictor of 6-month outcome at T0-1 h and T4-12 h, while miR-21 was predictive of the outcome at T4-12 h. The panel of selected miRNAs shows promise as biomarkers to discriminate mTBI from sTBI. In addition, the selected miRNAs represent new potential therapeutic targets.

UR - https://www.ncbi.nlm.nih.gov/pubmed/28279125

U2 - 10.1089/neu.2016.4857

DO - 10.1089/neu.2016.4857

M3 - Article

C2 - 28279125

VL - 34

SP - 1948

EP - 1956

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 11

ER -